ClinicalTrials.gg
CompletedNCT03797573Updated Jan 9, 2019

Multichannel tDCS to Reduce Hypertonia in Patients With Prolonged DOC

A Phase 1 interventional study of tDCS and sham tDCS in Vegetative State, Minimally Conscious State and Spasticity, Muscle, sponsored by University of Liege. Completed at 1 site in Belgium. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-01-09.

Sponsored by University of Liege · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 11 months after the study started (first participant enrolled Jan 2014, registered Jan 2019).
Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
16 Years to 75 Years
Sex
All
01

Study summary

Previous studies showed that transcranial direct current stimulation (tDCS) transiently improves performance of motor function in stroke patients, as well as decrease muscle hypertonia. In severely brain injured patients with disorders of consciousness (DOC), a single stimulation over the left dorsolateral prefrontal cortex has shown to improve patients' sign of consciousness. Nevertheless, other brain areas could be stimulated in order to manage other symptoms occurring in this population of patients, such as muscle hypertonia. In this study, investigators will assess the effects of bilateral fronto-central tDCS on spasticity as measured with the Modified Ashworth Scale (MAS) and on the Coma Recovery Scale-Revised (CRS-R) scores in patients with DOC in a double-blind sham-controlled experimental design.

Read the detailed description

Following severe brain damage and coma, some patients may remain in a vegetative state (VS) or minimally conscious state (MCS). At present, there are no evidence-based guidelines regarding the treatment of patients with disorders of consciousness (DOC). A previous study showed that a single stimulation (using transcranial direct current stimulation - tDCS) of the left prefrontal cortex induces an behavioral improvement in some patients in DOC. Nevertheless, patients with DOC suffer from other invalidating dysfunctions such as spasticity (muscle hypertonia). In sroke patients, the inhibition of the motor cortex through cathodes placed over the motor region showed to reduce spasticity.

In this study, investigators aim to assess the effect of single session of transcranial direct current stimulation (tDCS) over right and left fronto-central areas (using 2 anodes and 2 cathodes), on the level of hypertonia and the level of consciousness of patients with DOC, in a double blind randomized sham controlled study. The anodes will be placed over F3 and F4, and the cathodes over C3 and C4.

tDCS is a form of safe non-invasive cortical stimulation, modulating cortical excitability under the electrodes, via weak polarizing currents. It has been reported that anodal tDCS transiently improves motor functions in healthy subjects and patients with stroke or Parkinson's disease.

By reducing the activity of the motor cortex (cathodes) and increasing the activity of the prefrontal cortex (anodes) we expect to observe a better motor function in patients with DOC.

02

Conditions studied

  • Vegetative State
  • Minimally Conscious State
  • Spasticity, Muscle
  • Disorder of Consciousness

Keywords

  • transcranial direct current stimulation
  • disorder of consciousness
  • muscle hypertonia
  • spasticity
  • vegetative state
  • minimally conscious state
03

In context

Persistent Vegetative State

88 studies on the registry are indexed under Persistent Vegetative State; 20 are open to participants now.

This study's enrollment of 17 is below the median of 30 across 55 interventional studies indexed under Persistent Vegetative State.

Browse Persistent Vegetative State studies →

Lead sponsor

University of Liege is the lead sponsor of 251 studies on the registry; 50 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • post comatose patients
  • patients in minimally conscious state
  • patients with stable condition
  • patients free of sedative drugs and Na+ or Ca++ blockers (e.g., carbamazepine) or NMDA receptor antagonist (e.g., dextromethorphan)

Exclusion criteria

Exclusion Criteria:

  • premorbid neurology antecedent
  • patients in coma
  • patients \< 28 days after the acute brain injury
  • patients with a metallic cerebral implant
  • cranioplasty
  • shunt
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
17 participants (actual)

Study arms

  • Active comparator
    active tDCS

    Patients will receive tDCS (bilateral fronto-central stimulation) during 20 minutes preceded and followed by a clinical assessment (Modified Ashworth Scale and Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).

    Device: tDCS

  • Sham comparator
    sham tDCS

    Patients will receive sham tDCS (5 seconds of stimulation) during 20 minutes preceded and followed by a clinical assessment (Modified Ashworth Scale and Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).

    Device: sham tDCS

Interventions

  • DevicetDCS

    tDCS will be applied during 20 minutes with a current of 1 mA preceded and followed by a behavioral assessments (Modified Ashworth Scale and Coma Recovery Scale Revised) and an EEG. The anodes will be placed over F3 and F4 and the cathodes over C3 and C4.

  • Devicesham tDCS

    Indentical to the active tDCS, except that the stimulation is terminated after 5 seconds.

06

What researchers measure

Primary outcomes

  1. Change in MAS scores

    Modified Ashworth Scale (MAS) will by assessed before and after tDCS (active and sham). Comparison of treatment effect (MAS score after tDCS minus before) between active and sham tDCS. The MAS is a 5 points scale going from 0 (no spasticity) and 5 (extreme spasticity).

    Time frame: baseline and directly after tDCS (20 minutes)

Secondary outcomes

  1. Change in the CRS-R total score

    Coma Recovery Scale Revised (CRS-R) will be performed before and after tDCS (anodal and sham). Comparison of the treatment effect (CRS-R total score score after tDCS minus before) between real and sham tDCS. The CRS-R is 23 points scale with 6 sub-scales (lower scores refer to reflexes, while higher scores refer to more complex behaviors). The total score is the sum of the scores in the 6 sub-scales.

    Time frame: Baseline and directly after the tDCS (20 minutes)]

  2. Change in brain oscillations

    8 channels electroencephalography (EEG) will be record before and after tDCS to record potential cortical changes induce by the stimulation. EEG power will be compared in different bandwidths (delta, theta, alpha, beta).

    Time frame: Baseline and directly after the tDCS (20 minutes)

07

Study locations

1 site
  • University of Liege
    Liege, 4000, Belgium
08

References and documents

Publications

  • Thibaut A, Bruno MA, Ledoux D, Demertzi A, Laureys S. tDCS in patients with disorders of consciousness: sham-controlled randomized double-blind study. Neurology. 2014 Apr 1;82(13):1112-8. doi: 10.1212/WNL.0000000000000260. Epub 2014 Feb 26. PubMed 24574549 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03797573
Responsible party
Aurore Thibaut (Principal Investigator, University of Liege) — Principal investigator
First posted
Jan 9, 2019
Start date
Jan 20, 2014
Primary completion
Jun 28, 2014
Completion
Dec 13, 2017
Last update
Jan 9, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion